CYP2C19 and CYP3A4 gene variants and schizophrenia in Armenian patients

被引：0
|
作者：
Butenko, E. V. [1 ]
Mamedov, R. F. O. [1 ]
Ghazaryan, H. K. [2 ]
Zakharyan, R. V. [3 ]
机构：
[1] Southern Fed Univ, Rostov Na Donu, Russia
[2] Inst Mol Biol NAS RA, Yerevan, Armenia
[3] Russian Armenian Univ, Inst Mol Biol NAS RA, Yerevan, Armenia
来源：
EUROPEAN JOURNAL OF HUMAN GENETICS | 2019年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
P09.046B
引用
收藏
页码：269 / 270
页数：2
相关论文
共 50 条
  • [31] Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine
    Gruen, Barbara
    Merkel, Ulrike
    Riedel, Klaus-Dieter
    Weiss, Johanna
    Mikus, Gerd
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) : 854 - 863
  • [32] Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4
    Coller, JK
    Somogyi, AA
    Bochner, F
    XENOBIOTICA, 1999, 29 (10) : 973 - 986
  • [33] PHARMACOKINETICS OF ZOLPIDEM IN RELATION TO CYP2C19 GENOTYPE AFTER ADMINISTRATION OF CYP3A4 INHIBITOR
    Lee, Y. J.
    Byeon, J. Y.
    Kim, S. H.
    Kim, Y. H.
    Lee, H. J.
    Lee, Y.
    Kim, D. H.
    Lim, H. J.
    Jang, C. G.
    Lee, S. Y.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E138 - E139
  • [34] Analysis of the CYP2C19*2 and*3 gene variants in a Romanian population
    Buzoianu, A. D.
    Trifa, A. P.
    Popp, R. A.
    Militaru, C.
    Bocsan, C.
    Pop, I., V
    9TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS - EACPT, 2009, : 47 - +
  • [35] Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates
    Simon, Florian
    Gautier-Veyret, Elodie
    Truffot, Aurelie
    Chenel, Marylore
    Payen, Lea
    Stanke-Labesque, Francoise
    Tod, Michel
    PHARMACEUTICAL RESEARCH, 2021, 38 (03) : 415 - 428
  • [36] Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes
    Katsuki, H
    Hamada, A
    Nakamura, C
    Arimori, K
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (10) : 709 - 715
  • [37] Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population
    Hanioka, N.
    Tsuneto, Y.
    Saito, Y.
    Sumada, T.
    Maekawa, K.
    Saito, K.
    Sawada, J.
    Narimatsu, S.
    XENOBIOTICA, 2007, 37 (04) : 342 - 355
  • [38] Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole
    Walsh, T. J.
    Moriyama, B.
    Penzak, S. R.
    Klein, T. E.
    Caudle, K. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 190 - 190
  • [39] Pharmacogenetics of acenocoumarol:: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements
    Saraeva, R. B.
    Paskaleva, I. D.
    Doncheva, E.
    Eap, C. B.
    Ganev, V. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (06) : 641 - 649
  • [40] Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population
    Skadric, Ivan
    Stojkovic, Oliver
    INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 2020, 134 (02) : 433 - 439
12345